Surrozen (NASDAQ:SRZN – Get Free Report) and Whitehawk Therapeutics (NASDAQ:WHWK – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.
Profitability
This table compares Surrozen and Whitehawk Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Surrozen | -2,885.33% | N/A | -93.62% |
| Whitehawk Therapeutics | N/A | -53.89% | -49.97% |
Earnings & Valuation
This table compares Surrozen and Whitehawk Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Surrozen | $3.48 million | 99.05 | -$242.03 million | ($40.55) | -0.73 |
| Whitehawk Therapeutics | $7.14 million | 28.11 | -$20.60 million | ($1.12) | -3.14 |
Whitehawk Therapeutics has higher revenue and earnings than Surrozen. Whitehawk Therapeutics is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
66.6% of Surrozen shares are held by institutional investors. Comparatively, 52.1% of Whitehawk Therapeutics shares are held by institutional investors. 31.7% of Surrozen shares are held by company insiders. Comparatively, 49.9% of Whitehawk Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for Surrozen and Whitehawk Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Surrozen | 1 | 1 | 4 | 1 | 2.71 |
| Whitehawk Therapeutics | 1 | 0 | 7 | 0 | 2.75 |
Surrozen currently has a consensus price target of $48.33, suggesting a potential upside of 62.79%. Whitehawk Therapeutics has a consensus price target of $8.33, suggesting a potential upside of 136.74%. Given Whitehawk Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Whitehawk Therapeutics is more favorable than Surrozen.
Risk & Volatility
Surrozen has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500. Comparatively, Whitehawk Therapeutics has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500.
Summary
Whitehawk Therapeutics beats Surrozen on 10 of the 15 factors compared between the two stocks.
About Surrozen
Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.
About Whitehawk Therapeutics
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.
Receive News & Ratings for Surrozen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surrozen and related companies with MarketBeat.com's FREE daily email newsletter.
